Advertisement

Biochemical Genetics

, Volume 47, Issue 9–10, pp 688–693 | Cite as

Apolipoprotein E Polymorphism in Hemodialyzed Patients and Healthy Controls

  • Jaroslav A. Hubacek
  • Silvie Bloudickova
  • Ruzena Kubinova
  • Hynek Pikhart
  • Ondrej Viklicky
  • Martin Bobak
Article

Abstract

A possible association between end-stage renal disease (ESRD) and apolipoprotein E (APOE) polymorphism was found in some but not all studies. We have analyzed the APOE genotypes in 995 hemodialyzed patients (cases) and a sample of 6242 healthy individuals (controls) in the Czech Republic. There was a statistically significant difference in the frequency of APOE alleles between cases and controls, with more carriers of the APOE2 allele in ESRD patients (15.9%) than in controls (12.2%) (P = 0.005). The odds ratio of ESRD for the APOE2 allele, compared with APOE3E3 homozygotes, was 1.37 (95% confidence interval 1.13–1.67). The strength of the association increased with the time spent on hemodialysis: the odds ratio of all-cause ESRD in patients dialyzed for eight or more years was 1.27 (0.94–1.71), for 1–8 years 1.41 (1.09–1.81), and less than 1 year (nonsurvivors) 1.94 (0.88–4.18). This study suggests that the APOE2 allele is a possible genetic risk factor for all-cause ESRD in Caucasians.

Keywords

Apolipoprotein E End-stage renal disease Polymorphism 

Notes

Acknowledgments

The project was supported by project no. NR 7958-5, IGA MH Czech Republic. The HAPIEE study is funded by the Wellcome Trust and the U.S. National Institute of Aging. We thank the participating clinicians (P. Táborský, FMC Prague; V. Polakovič and M. Sezamová, VFN Prague 6; E. Svítilová, Ústí nad Labem; J. Vlasák and I. Sojková, FMC Sokolov; M. Ryba, Liberec; P. Knetl, Jihlava; M. Ullrych, Děčín; R. Drahozal, Dialcorp Prague; V. Pavuková, Chomutov; B. Pavlíková, Uherské Hradiště; D. Fischlová, Kladno; M. Mokrejšová, VFN Prague; H. Chmelíčková, Třebíč; E. Pauchová, Prachatice; P. Vyskočil, Louny; Z. Nýdlová, Strakonice; J. Kopenec, Benešov; P. Fixa, Hradec Králové; J. Hajný, Chrudim; P. Bubeníček and P. Syrovátka, IKEM Prague; J. Zahálková, Olomouc; S. Šurel, Brno; Z. Hobzek, Písek; A. Hrubý, FMC Slavkov; J. Suchanová, Tábor; S. Vaňková, Eurocare Prague; J. Brabcová, Blansko) for collecting patient samples. We also thank workers in the National and Regional Institutes of Public Health who collected data on the population sample (controls).

References

  1. Arikan H, Koc M, Sari H, Tuglular S, Ozener C, Akoglu E (2007) Association between apolipoprotein E gene polymorphism and plasminogen activator inhibitor-1 and atherogenic lipid profile in dialysis patients. Ren Fail 29:713–719PubMedCrossRefGoogle Scholar
  2. Chen G, Paka L, Kako Y, Singhal P, Duan W, Pillarisetti S (2001) A protective role for kidney apolipoprotein E. Regulation of mesangial cell proliferation and matrix expansion. J Biol Chem 276:49142–49147PubMedCrossRefGoogle Scholar
  3. Davignon J, Gregg RE, Sing CF (1988) Apolipoprotein E polymorphism and atherosclerosis. Atherosclerosis 8:1–21Google Scholar
  4. Feussner G, Wey S, Bommer J, Deppermann D, Grützmacher P, Ziegler R (1992) Apolipoprotein E phenotypes and hyperlipidemia in patients under maintenance hemodialysis. Hum Genet 88:307–312PubMedCrossRefGoogle Scholar
  5. Gerdes LU, Klausen IC, Sihn I, Faergeman O (1992) Apolipoprotein E polymorphism in a Danish population compared to findings in 45 other study population around the world. Genet Epidemiol 9:155–167PubMedCrossRefGoogle Scholar
  6. Gross ML, Amann K (2004) Progression of renal disease: new insights into risk factors and pathomechanisms. Curr Opin Nephrol Hypertens 13:307–312PubMedCrossRefGoogle Scholar
  7. Güz G, Nurhan Ozdemir F, Sezer S, Işiklar I, Arat Z, Turan M, Haberal M (2000) Effect of apolipoprotein E polymorphism on serum lipid, lipoproteins, and atherosclerosis in hemodialysed patients. Am J Kidney Dis 36:826–836PubMedCrossRefGoogle Scholar
  8. Hixson JE, Vernier DT (1990) Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res 31:545–548PubMedGoogle Scholar
  9. Horita K, Eto M, Makino I (1994) Apolipoprotein E, renal failure and lipid abnormalities in non-insulin-dependent diabetes mellitus. Atherosclerosis 107:203–211PubMedCrossRefGoogle Scholar
  10. Hubacek JA, Pitha J, Stávek P, Poledne R (2000) Variable expression of hypercholesterolemia in apolipoprotein E2* (Arg136 → Cys) heterozygotes. Physiol Res 49:307–314PubMedGoogle Scholar
  11. Hubacek JA, Bloudíčková S, Bohuslavová R, Táborský P, Polakovic V, Sazamová M, Svítilová E, Vlasák J, Sojková I, Ryba M, Knetl P, Ullrych M, Drahozal R, Pavuková V, Pavlíková B, Fischlová D, Mokrejsová M, Chmelícková H, Pauchová E, Vyskocil P, Nýdlová Z, Kopenec J, Fixa P, Hajný J, Bubenícek P, Syrovátka P, Zahálková J, Surel S, Hobzek Z, Hrubý A, Suchanová J, Vanková S, Brabcová J, Viklický O, MIA Group (2007) Ghrelin variants influence development of body mass index and plasma levels of total cholesterol in dialyzed patients. Clin Chem Lab Med 45:1121–1123PubMedCrossRefGoogle Scholar
  12. Leblanc M, Kellum JA, Gibney RT, Lieberthal W, Tumlin J, Mehta R (2005) Risk factors for acute renal failure: inherent and modifiable risks. Curr Opin Crit Care 11:533–536PubMedCrossRefGoogle Scholar
  13. Liberopoulos E, Siamopoulos K, Elisaf M (2004) Apolipoprotein E and renal disease. Am J Kidney Dis 43:223–233PubMedCrossRefGoogle Scholar
  14. Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acid Res 16:1215PubMedCrossRefGoogle Scholar
  15. Moeller S, Gioberge S, Brown G (2002) ESRD patients in 2001: global overview of patients, treatment modalities and development trends. Nephrol Dial Transplant 17:2071–2076PubMedCrossRefGoogle Scholar
  16. Nordfors L, Lindholm B, Stenvinkel P (2005) End-stage renal disease—not an equal opportunity disease: the role of genetic polymorphisms. J Intern Med 258:1–12PubMedCrossRefGoogle Scholar
  17. Oda H, Yorioka N, Ueda C, Kushikata S, Yamakido M (1999) Apolipoprotein E polymorphism and renal disease. Kidney Int Suppl 71:S25–S27PubMedCrossRefGoogle Scholar
  18. Peasey A, Bobak M, Kubinova R, Malyutina S, Pajak A, Tamosiunas A, Pikhart H, Nicholson A, Marmot M (2006) Determinants of cardiovascular disease and other non-communicable diseases in Central and Eastern Europe: rationale and design of the HAPIEE study. BMC Public Health 6:255PubMedCrossRefGoogle Scholar
  19. Pecoits-Filho R, Lindholm B, Stenvinkel P (2002) The malnutrition, inflammation, and atherosclerosis (MIA) syndrome—the heart of the matter. Nephrol Dial Transplant 17(Suppl 11):28–31PubMedGoogle Scholar
  20. Roussos L, Ekström U, Ehle PN, Oqvist B, Floren CH (2004) Apolipoprotein E polymorphism in 385 patients on renal replacement therapy in Sweden. Scand J Urol Nephrol 38:504–510PubMedCrossRefGoogle Scholar
  21. Svobodova H, Kucera F, Stulc T, Vrablík M, Amartuvshin B, Altannavch Ts, Ceska R (2007) Apolipoprotein E gene polymorphism in the Mongolian population. Folia Biol (Praha) 53:138–142Google Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Jaroslav A. Hubacek
    • 1
    • 2
    • 3
  • Silvie Bloudickova
    • 1
  • Ruzena Kubinova
    • 4
  • Hynek Pikhart
    • 5
  • Ondrej Viklicky
    • 1
  • Martin Bobak
    • 5
  1. 1.Institute for Clinical and Experimental Medicine, CEM, Laboratory for Molecular GeneticsPrague 4Czech Republic
  2. 2.Third Internal Department, First Medical FacultyCharles UniversityPragueCzech Republic
  3. 3.Cardiovascular Research CentrePragueCzech Republic
  4. 4.National Institute of Public HealthPragueCzech Republic
  5. 5.Department of Epidemiology and Public HealthUniversity College LondonLondonUK

Personalised recommendations